Investing.com -- Novo Nordisk (NYSE: NVO) has appointed Maziar Mike Doustdar as its new president and chief executive officer ...

Novo Nordisk (NYSE:NVO) announced on Tuesday that Maziar Mike Doustdar will become its new president and chief executive ...

In India, Zaynich will be positioned as a third-line treatment, primarily for ICU patients when other antibiotics have failed ...

Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective ...

Bagsværd, Denmark, 29 July 2025 - Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds La ...

The FDA has cleared investigational new drug applications for ZW251 and RV‑01, advancing novel treatments for solid tumors in first-in-human trials.

Vinay Prasad leaves FDA apparently due to backlash from the agency's handling of potential deaths related to Sarepta's ...

Presentation to highlight the Company's proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company's Phase 1b clinical trial design and ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced the appointment of Roland Kolbeck, Ph.D., as its new Chief Scientific ...

Mr. Joel Hassman Samuels has accepted the role of Provost, and will begin on Aug. 11, 2025. After two years of Willy Prado ...

Atossa’s progress reflects the strong strategic momentum promised in the March 11, 2025 announcement of a metastatic focus; momentum that aligns well with FDA expectations and regulatory standards, ...

U.S. President Donald Trump is playing 18 holes on his new golf course in Scotland as pressure grows for him to address ...